With two blockbuster products set to lose patent protection in the next two to three years, Eli Lilly and Co. certainly seems like a firm that would be willing to pay $70 per share - about $6.1 billion - to acquire ImClone Systems Inc., though the big pharma firm has neither confirmed nor denied that it is the unnamed bidder that topped Bristol-Myers Squibb Co.'s offer earlier this year. (BioWorld Today)